Andreas Voss Net Worth

Andreas Voss biography

Dr. Andreas Voss has been appointed an Independent Director at Celsion Corporation effective December 15, 2015. Dr. Voss currently serves as Vice President of Clinical Affairs in Europe at Caris Life Sciences, a biotechnology company focused on implementing personalized medicine in oncology through its liquid biopsy technology. Prior to joining Caris in 2010, he was responsible for the global clinical development of Avastin® and a member of the Corporate Drug Safety Board at F. Hoffmann-La Roche. Before joining Roche in 2006, he was Medical Director for the Lung Cancer Disease Area at AstraZeneca, and from 2000 to 2003, he was the Medical Director for Anti-infectives and Oncology at Bayer GmbH. From 1996 to 2000, Dr. Voss was Head of Medical Research, Oncology at Asta Medica AG. Dr. Voss received his M.D. from the University of Hamburg Medical School and was a postdoctoral fellow at the University of California at San Diego. He is board certified in internal medicine.

What's Andreas Voss's mailing address?

Andreas's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.

Insiders trading at Imunon Inc

Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link, and Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.

What does Imunon Inc do?

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

Imunon Inc executives and stock owners

Imunon Inc executives and other stock owners filed with the SEC include:

• Michael Tardugno,
  Executive Chairman of the Board, President, Chief Executive Officer
• Michael H. Tardugno,
  Exec. Chairman, Pres & CEO
• Nicholas Borys,
  Senior Vice President and Chief Medical Officer
• Jeffrey Church,
  Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
• Dr. Nicholas Borys,
  Exec. VP & Chief Medical Officer
• Jeffrey W. Church CPA, CPA,
  CFO, Exec. VP & Corp. Sec.
• Dr. Khursheed Anwer M.B.A., Ph.D.,
  Exec. VP & Chief Scientific Officer
• Khursheed Anwer,
  Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
• Dr. Khursheed Anwer,
  Exec. VP & Chief Scientific Officer
• Andreas Voss,
  Independent Director
• Alberto Martinez,
  Independent Director
• Robert Hooper,
  Independent Director
• Frederick Fritz,
  Independent Director
• Pok Yu Chow,
  Independent Director
• Donald Braun,
  Independent Director
• Marianne M. Lambertson,
  VP of Communications & Investor Relations
• Timothy J. Tumminello,
  Chief Accounting Officer & Controller
• Sean F. Moran,
  Chief Financial Officer
• Gary W Pace,
  Director
• Stacy Lindborg,
  Director
• Christine A Pellizzari,
  Director
• Timothy J Tumminello,
  Controller
• Inc. Fka Egen, Inc. Egwu,,
  10% owner
• Max Link,
  Director
• Gregory L Weaver,
  Director
• Goff Corinne Le,
  President and CEO
• Constantine John Kardaras,
  Chief Accounting Officer